Seres Therapeutics appoints Richard Kender as interim CEO
Source: SeekingAlpha
2026-03-02 16:24:02 ET
More on Seres Therapeutics
- Seres Therapeutics: Strong SER-155 Data, But Dilution Risk Now Warrants A 'Hold'
- Seres down after pausing investments for lead program
- Seeking Alpha’s Quant Rating on Seres Therapeutics
- Historical earnings data for Seres Therapeutics
- Financial information for Seres Therapeutics
Read the full article on Seeking Alpha
For further details see:
Seres Therapeutics appoints Richard Kender as interim CEO
Seres Therapeutics Inc.
NASDAQ: MCRB
MCRB Trading
0.54% G/L:
$9.23 Last:
9,048 Volume:
$9.32 Open:
MCRB Latest News
March 02, 2026 04:05:00 pm
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
February 12, 2026 07:00:00 am
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases
January 06, 2026 07:00:00 am
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst(TM) Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy
November 05, 2025 07:00:00 am
Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
MCRB Stock Data
$129,727,082
7,418,146
0.38%
16
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
